FMS
Fresenius Medical·NYSE
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 3
Bearish signal 1
High Cash/net Profit Ratio
Revenue Beats Expectation
Bullish Abandoned Baby
EPS Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About FMS
Fresenius Medical Care Ag
The nation's leading provider of kidney care services
Healthcare Providers and Services
08/05/1996
10/01/1996
New York Stock Exchange
111,513
12-31
Depository Receipts (Ordinary Shares)
Else-Kroner Strasse 1, 61352 Bad Homburg, Germany
--
Fresenius Medical Care AG was originally established as a joint stock company on August 5, 1996 and registered as a joint stock company on February 10, 2006. The company is a German partnership (Kommanditgesellschaft auf Aktien), the world's largest kidney dialysis company, operating in the field of dialysis care and dialysis products for the treatment of end-stage renal disease (" ESRD "). In addition to providing dialysis treatment, the Company's dialysis care business includes pharmacy services and vascular access surgery services (collectively referred to as "extended services "). The Company's dialysis products business includes the manufacture and distribution of products for the treatment of ESRD. The Company's dialysis business is vertically integrated, providing dialysis treatment to the dialysis clinics it owns or operates and offering a wide range of products to those clinics. In addition, the company sells dialysis products to other dialysis service providers. In the United States (" U.S. "), the company also provides laboratory testing services, as well as inpatient dialysis services and other services under contract with hospitals.
Earnings Call
Q3/2025
Estimate EPS0.57455
Actual EPS1.10309
Estimate Revenue5.50B
Actual Revenue5.73B
Fresenius Medical Care's Q3 2025 Earnings Call: Contradictions in Patient Inflow, Medicare Enrollment, and Pharma Guidance
Nov 04,2025 10:04
Earnings Decrypt
Earnings Decrypt
Company Financials
EPS
FMS has released its 2023 Q4 earnings. EPS was reported at 0.47, versus the expected 0.32, beating expectations. The chart below visualizes how FMS has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
FMS has released its 2025 Q3 earnings report, with revenue of 5.73B, reflecting a YoY change of 8.05%, and net profit of 384.14M, showing a YoY change of 30.56%. The Sankey diagram below clearly presents FMS's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
